With over USD10 billion in sales, the VA FSS Service supports the healthcare requirements of the VA and other federal government agencies by providing Federal customers with access to over 1 million state-of-the-art commercial products and services. The listing, which went into effect on October 2, will include the combination treatment on the FSS catalogue and make it available for purchase by Veterans Affairs and Department of Defense facilities.
"We are pleased that the VA FSS has begun to list Ameluz® and our combination BF-RhodoLED® lamp as a treatment option for skin cancer precursors. This listing represents another significant milestone for our company in the U.S. market," said Prof. Dr. Hermann Lübbert, CEO of Biofrontera. "The VA FSS expands our opportunity to reach new patients and demonstrates the demand for efficacious treatment. It further validates our technology as an effective treatment for skin cancer precursors, as well as provides more patients with the opportunity to receive treatment."
Interested facilities should follow normal ordering procedures and can reach out directly to the following:
Enquiries, please contact:
Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0
IR Germany: Brainwell Asset Solutions
+49 (0) 152 08931514
IR UK: Seton Services
+44(0) 20 7729 0805
IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas
Biofrontera AG is a biopharmaceutical company specializing in the development, sale and distribution of dermatological drugs and medical cosmetics.
The Leverkusen, Germany-based company, which has approximately 130 employees worldwide, develops and distributes innovative products for the care, protection and treatment of the skin. Biofrontera's combination lead product is topical prescription drug Ameluz® and medical device BF-RhodoLED® for the photodynamic therapy (PDT) treatment of superficial skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the U.S. since 2016. The Company also markets the Belixos® dermocosmetics series in the EU, which offers specialized care for damaged or diseased skin.
Biofrontera is the first German, founder-led pharmaceutical company to obtain both EU and U.S. approval for a medical drug it has developed itself. The Biofrontera Group was established in 1997 by current CEO, Prof. Dr. Hermann Lübbert, and is listed on the Frankfurt Stock Exchange (Prime Standard).
This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements. (end)
Hemmelrather Weg 201
|contact person:||Investor & public relations|
|phone:||+49 (0) 214 87 63 20|
|stock exchanges:||regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate|